Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
76 hedge funds and large institutions have $294M invested in Avadel Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 16 closing their positions.
156% more call options, than puts
Call options by funds: $7.6M | Put options by funds: $2.97M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more capital invested
Capital invested by funds: $211M → $294M (+$83.2M)
1.01% more ownership
Funds ownership: 54.98% → 56% (+1%)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
7% less funds holding
Funds holding: 82 → 76 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$4.88M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$4.67M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.15M |
| 4 |
RI
RTW Investments
New York
|
+$2.87M |
| 5 |
GJL
Gendell Jeffrey L
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.76M |
| 2 |
Millennium Management
New York
|
-$2.29M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.97M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$1.88M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$1.56M |
AVDL Hedge Fund Activity: Q1 2021 in Review
76 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2021, worth a combined $294M — up 39% from $211M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AVDL and 10 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was Cowen and Company, adding an estimated $4.88M. The largest seller was Vivo Capital, cutting an estimated $4.76M.
- 76 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2021, down from 82 in Q4 2020.
- Funds reported $294M of Avadel Pharmaceuticals stock for Q1 2021, up 39% quarter-over-quarter.
- 10 funds opened new Avadel Pharmaceuticals positions in Q1 2021 and 16 closed out, a net change of -6 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2021 was Cowen and Company, an estimated $4.88M added.
- The largest Avadel Pharmaceuticals seller in Q1 2021 was Vivo Capital, an estimated $4.76M sold.
Based on aggregated 13F filings for Q1 2021.